Vir Biotechnology

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vir Biotechnology reports Q2 results, focuses on breakthrough therapies

Vir Biotechnology's Q2 2023 performance reflects strong financial discipline and a focus on advancing breakthrough therapies for infectious diseases.
Despite challenges in trial outcomes and treatment durations, Vir's robust cash position and diverse pipeline position it well for future growth.
The company's strategic strengths in capitalization, pipeline diversity, and commitment to medical innovation present promising opportunities for continued success.

Vir Biotechnology reports Q3 loss, eyes growth in diverse sectors

Vir Biotechnology's Q3 2023 performance reflected revenue decline, high R&D expenses, and a consolidated net loss, offset by strong financial position.
Strengths include a robust financial standing, advancements in next-generation antibodies, and application of trial learnings to enhance analysis.
Challenges encompass expansion into new sectors, regulatory criteria, and dose calibration, while opportunities exist in HIV programs and strategic expansions.
Overall, Vir Biotechnology navigates financial challenges with a focus on innovation and growth in diverse therapeutic areas.

Vir Biotechnology advances hepatitis treatments amidst financial growth and challenges

Vir Biotechnology's Q4 2023 performance reflects progress in drug development for hepatitis delta, hepatitis B, and HIV, supported by a strong financial position.
While facing challenges such as leadership transitions and pipeline restructuring, the company remains focused on clinical trial enrollment and cost management.
Opportunities lie in sharing trial data, expanding treatment regimens, and collaborating for improved disease management, positioning Vir for future growth and innovation.
Strategic allocation of resources and a commitment to advancing therapeutic solutions underscore Vir's resilience and potential for long-term success in the biopharmaceutical industry.

Vir Biotechnology excels in Q1 trials, eyes transformative growth

Vir Biotechnology's Q1 performance reflects progress in clinical trials and strategic initiatives, positioning the company for transformative growth in 2024.
Despite leadership changes and regulatory challenges, Vir Biotechnology's strong pipeline and global study designs offer resilience and potential for market success.
The upcoming data presentations and trial milestones present key opportunities for Vir Biotechnology to solidify its position in the biopharmaceutical industry and drive shareholder value.

Vir Biotechnology reports breakthrough results in hepatitis delta treatment

Vir Biotechnology's Q3 2024 earnings call highlighted promising results from the SOLSTICE trial in chronic hepatitis delta and strategic collaborations with Sanofi.
The company's financial performance and pipeline updates demonstrate a strong foundation for growth and innovation in the biopharmaceutical industry.
While facing challenges in regulatory complexities and financial management, Vir Biotechnology remains well-positioned to capitalize on opportunities in transformative therapies.
Overall, Vir's focus on advancing hepatitis programs and T-cell engagers underscores a commitment to addressing critical medical needs and driving shareholder value.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vir Biotechnology presents a unique investment opportunity with a promising pipeline of viral therapeutics targeting hepatitis B, HIV, and influenza A, backed by strong financials and strategic collaborations. Vir's robust financial portfolio, effective cost-cutting measures, and commitment to R&D demonstrate a forward-thinking approach to sustainable growth. Despite facing competition, Vir's innovative products, such as VIR-2218 and VIR-3434 for chronic HBV infection, and VIR-1111 and VIR-1388 for HIV, have the potential to provide more comprehensive and sustained immune responses against diverse viral strains.

Vir Biotechnology Unveils Hidden Value: Innovation, Strategic Partnerships Drive Investment Potential

– Data support the potential impact of VIR-2218 and VIR-3434 in addressing both HBV and HDV and underscore the Company's confidence in its approach to a functional cure for HBV – – Data support the potential impact of VIR-2218 and VIR-3434 in addressing both HBV and HDV and underscore the Company's confidence in its approach to a functional cure for HBV –

Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B and D Data Accepted for Presentation at EASL™ Congress 2023

SAN FRANCISCO, June 05, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, is scheduled to participate in a fireside chat at the 44th Annual Goldman Sachs Global Healthcare Conference on Monday, June 12, at 10:40 a.m. PT / 1:40 p.m. ET.

Vir Biotechnology to Participate in the 44th Annual Goldman Sachs Global Healthcare Conference

SAN FRANCISCO, May 17, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today reminds stockholders that it will hold its 2023 Annual General Meeting of Stockholders on Friday, May 19, 2023, at 11:30 a.m. PT. The Annual Meeting will be held in virtual format only via live audio webcast.

Vir Biotechnology to Host a Virtual-Only 2023 Annual Meeting of Stockholders

SAN FRANCISCO, May 15, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Jeff Calcagno, M.D., as Executive Vice President and Chief Business Officer. Dr. Calcagno will be responsible for leading the Company's business development efforts, optimizing existing alliances and establishing new strategic industry and public-private partnerships. He reports to Vir's Chief Executive Officer Marianne De Backer, M.Sc., Ph.D., MBA, and joins Vir's executive management team.

Vir Biotechnology Appoints Jeff Calcagno, M.D., as Executive Vice President and Chief Business Officer

– STRIVE is the first Phase 2 sub-protocol trial initiated under Vir's new PREVAIL platform trial investigating the Company's novel therapies in two chronic hepatitis B virus patient populations –

Vir Biotechnology Announces First Patient Dosed in New Phase 2 Chronic Hepatitis B Virus Trial Evaluating Combinations of VIR-2218, VIR-3434, PEG-IFNα and an NRTI

Celanese

Kulicke & Soffa Industries

Albemarle

Marathon Petroleum

Sibanye Stillwater

While the benchmark S&P 500 index may be up for the year, investors should consider acquiring the below top-rated stocks to buy. One key reason is that momentum appears to be fading.

7 Top-Rated Stocks That Will Boost Your Portfolio in 2023

Deswell Industries

Photronics

BioNTech SE

Chicago Rivet & Machine

Gravity Co

Although the Federal Reserve aggressively targeted inflation since last year, consumer prices remain stubbornly high, thus incentivizing the case for the best bargain stocks to buy this month. Let's face it – everybody appreciates a good discount.

The 7 Best Bargain Stocks to Buy for May 2023

– Multiple data readouts anticipated in 2023 from ongoing Phase 2 programs in hepatitis B and D, and influenza –

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2023 Financial Results

SAN FRANCISCO, May 03, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, is scheduled to present at the BofA Securities 2023 Health Care Conference on Wednesday, May 10, at 8:00 a.m. PT / 11:00 a.m. ET.

Vir Biotechnology to Participate in the BofA Securities 2023 Health Care Conference

– New grant from the Bill & Melinda Gates Foundation supports the Phase 1 development of VIR-1388, an investigational HIV T cell vaccine based on a novel vector –

Vir Biotechnology Receives Expanded Support to Develop Its Novel T Cell Vaccine Platform with New $10 Million Grant for HIV Prevention

Vir Biotechnology, Inc. (VIR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Vir Biotechnology, Inc. (VIR) Q1 Earnings Expected to Decline

SAN FRANCISCO, April 11, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., Executive Vice President, Chief Medical Officer and Interim Head of Research, is scheduled to participate in a fireside chat at the 22nd Annual Needham Virtual Healthcare Conference on Tuesday, April 18, at 12:00 p.m. PT / 3:00 p.m. ET.

Vir Biotechnology to Participate in the 22nd Annual Needham Virtual Healthcare Conference

AbCellera Biologics

Chimerix

Kiniksa Pharmaceuticals Ltd

Ocuphire Pharma

Point Biopharma Global

Vaccitech

While it might be difficult to navigate the equities sector now amid various headwinds, biotech stocks to buy may offer a surprising respite. True, the market presence of the surprise production cuts by the Organization of the Petroleum Exporting Countries (OPEC) and non-member oil-producing nations — known as OPEC+ — along with the Federal Reserve's possible response.

7 Thrilling Biotech Stocks for Aggressive Investors to Buy

Investors need to pay close attention to Vir Biotechnology (VIR) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Vir Biotechnology (VIR) Stock?

SVB Financial Group

Axsome Therapeutics

Rhythm Pharmaceuticals

The collapse of SVB will leave early-stage biotech companies in a funding dearth. But big-name biotech stocks will emerge largely untouched.

Biotech Stocks And The SVB Collapse — Here's What We Know

The collapse of Silicon Valley Bank will leave early-stage biotechnology companies with a funding void, investors and analysts said on Monday, but larger, publicly-traded drug companies should escape unscathed.

SVB fall casts shadow on early-stage U.S. biotech

SAN FRANCISCO, March 08, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., Executive Vice President, Chief Medical Officer and Interim Head of Research, is scheduled to present at the Barclays Global Healthcare Conference on Wednesday, March 15, at 7:15 a.m. PT / 10:15 a.m. ET.

Vir Biotechnology to Participate in the Barclays Global Healthcare Conference

Aptevo Therapeutics

Beam Therapeutics

Dynavax Technologies

iTeos Therapeutics, Inc.

Biotech stocks almost always have the potential for significant growth over time. Companies in the sector operate in areas including drug development, medical devices, and diagnostics.

The Top 7 Growth Stocks in Biotech

SAN FRANCISCO, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Bolyn Hubby, Ph.D., Executive Vice President and Chief Corporate Affairs Officer, will participate in a panel focused on infectious diseases at the Cowen 43rd Annual Health Care Conference on Tuesday, March 7, at 6:10 a.m. PT / 9:10 a.m. ET.

Vir Biotechnology to Participate in the Cowen 43rd Annual Health Care Conference

Vir Biotechnology, Inc. (VIR) delivered earnings and revenue surprises of -1,800% and 80.07%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Misses Revenue Estimates

– Transformational year ahead with critical Phase 2 readouts expected for programs in hepatitis B, hepatitis D and influenza with the potential for significant patient impact –

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results

Final draft guidance based on cost effectiveness evaluation of sotrovimab Final draft guidance based on cost effectiveness evaluation of sotrovimab

Vir Biotechnology Announces Positive Final Draft Guidance on Sotrovimab from the UK's National Institute for Health and Care Excellence (NICE)

Vir Biotechnology Inc (NASDAQ: VIR) jumped nearly 10% this morning after a Goldman Sachs analyst turned super bullish on the clinical-stage immunology company.

This biotech stock could double from here: Goldman Sachs

SAN FRANCISCO, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the fourth quarter and full year ended December 31, 2022, on Thursday, February 23, 2023.

News for Vir Biotechnology Stock (VIR)